000			02914cam a2200349 a 4500
003			EG-GiCUC
005			20250223032412.0
008			191008s2019 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.28.M.Sc.2019.Ma.A
100	0		_aMarwa Mohammed Elsayed Abdelmonaem
245	1	0	_aAssessment of glucose tolerance in nephropathic cystinosis patients / _cMarwa Mohammed Elsayed Abdelmonaem ; Supervised Neveen Abdelmonem Soliman , Noha Arafa Mohammed , Ghada Maher Mohamed
246	1	5	_aتقييم تفاوت مستوى السكر في الدم في مرضى داء السيستين
260			_aCairo : _bMarwa Mohammed Elsayed Abdelmonaem , _c2019
300			_a138 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520			_aBackground: Nephropathic cystinosis is a rare genetic disease characterized by accumulation of the amino acid cystine in lysosomes throughout the body. Diabetes mellitus remain a major complication of nephropathic cystinosis. Methods: Assessment of glucose metabolic status among sixteen patients with confirmed nephropathic cystinosis aged three years or more using OGTT and HbA1C. Evaluation of pancreatic Ý cell functions using 2-hour postprandial c-peptide values. Results: The study included 16 patients their age ranged from 4 to 21 years. Their age at diagnosis of nephropathic cystinosis ranged from 5 to 96 months. The incidence of abnormal glucose metabolism among our cohort of patients with nephropathic cystinosis was 4 patients (25%). One patient (6.2%) had both impaired fasting glucose (IFG) and IGT; one patient (6.2%) had only impaired glucose tolerance (IGT). Another two patients (12.5%) showed diabetic levels blood glucose during OGTT. Four patients had impaired HbA1C > 6%. Ten patients had elevated 2-hour postprandial c-peptide > 7.1 ng/ml. Conclusion: All patients with nephropathic cystinosis are at risk of developing diabetes mellitus as a complication of CTN during adolescence or adulthood if they are not compliant to treatment, or 10 years after renal transplantation due to steroid and tacrolimus use. Nevertheless, there is a pressing need enhance patient compliance for oral cysteamine and steroid sparing protocol of immunosuppressive drugs and use cyclosporine instead of tacrolimus to improve outcome
530			_aIssued also as CD
653		4	_aImpaired fasting glucose
653		4	_aNephropathic cystinosis
653		4	_aOral glucose tolerance test
700	0		_aGhada Maher Mohamed , _eSupervisor
700	0		_aNeveen Abdelmonem Soliman , _eSupervisor
700	0		_aNoha Arafa Mohammed , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAsmaa _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c74340 _d74340